

NUPLAZID is indicated for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis

Did you know? NUPLAZID capsules can be opened and sprinkled



Once-daily dose, taken whole or sprinkled¹

The capsule can be opened and the entire contents sprinkled over a tablespoon (15 mL) of applesauce, yogurt, pudding, or a liquid nutritional supplement. The drug/food mixture should be consumed immediately without chewing; do not store for future use.¹



- Taken orally¹
- No titration needed¹
- Taken with or without food¹
- Taken whole or sprinkled¹

(Not actual size)*

*Actual size is 14.4 mm x 5.3 mm.

Dosing Considerations

- For patients taking strong CYP3A4 inhibitors, the recommended dose of NUPLAZID is 10 mg once daily¹
- Avoid concomitant use of strong or moderate CYP3A4 inducers with NUPLAZID¹
- Avoid the use of NUPLAZID in patients with known QT prolongation or in combination with other drugs known to prolong the QT interval^{††}
- NUPLAZID does not require a dosage adjustment in elderly patients, in patients with mild to severe renal impairment or end-stage renal disease (ESRD),[‡] or in patients with hepatic impairment¹
- The steady-state plasma concentration of NUPLAZID was reached in ~12 days with continuous treatment, without titration²
 - Half-life ($t_{1/2}$) is 57 hours¹
- No dosage adjustment of carbidopa/levodopa is required when administered concomitantly with NUPLAZID¹

[†]In the 6-week placebo-controlled Parkinson's disease psychosis studies, NUPLAZID prolonged the QT interval (mean increase ~5-8 ms).¹

[‡]Increased exposure (C_{max} and AUC) to NUPLAZID occurred in patients with severe renal impairment ($CrCl < 30$ mL/min, Cockcroft-Gault) in a renal impairment study. NUPLAZID should be used with caution in patients with severe renal impairment and ESRD.¹

Indication and Important Safety Information

Indication

NUPLAZID is indicated for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis.

Important Safety Information

WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS

- Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death.
- NUPLAZID is not approved for the treatment of patients with dementia-related psychosis unrelated to the hallucinations and delusions associated with Parkinson's disease psychosis.

See additional Important Safety Information on the next page. Please read the accompanying full [Prescribing Information](#), including **Boxed WARNING**, also available at NUPLAZIDhcp.com.

ONCE-DAILY
NUPLAZID[®]
(pimavanserin) 34mg capsules

Make NUPLAZID part of your treatment plan

- Once-daily dose, taken whole or sprinkled¹

The capsule can be opened and the entire contents sprinkled over a tablespoon (15 mL) of applesauce, yogurt, pudding, or a liquid nutritional supplement. The drug/food mixture should be consumed immediately without chewing; do not store for future use.¹



For more information, visit [NUPLAZIDhcp.com](https://www.nuplazidhcp.com)

Important Safety Information (cont'd)

- **Contraindication:** NUPLAZID is contraindicated in patients with a history of a hypersensitivity reaction to pimavanserin or any of its components. Rash, urticaria, and reactions consistent with angioedema (e.g., tongue swelling, circumoral edema, throat tightness, and dyspnea) have been reported.
- **Warnings and Precautions:** QT Interval Prolongation
 - NUPLAZID prolongs the QT interval. The use of NUPLAZID should be avoided in patients with known QT prolongation or in combination with other drugs known to prolong QT interval including Class 1A antiarrhythmics or Class 3 antiarrhythmics, certain antipsychotic medications, and certain antibiotics.
 - NUPLAZID should also be avoided in patients with a history of cardiac arrhythmias, as well as other circumstances that may increase the risk of the occurrence of torsade de pointes and/or sudden death, including symptomatic bradycardia, hypokalemia or hypomagnesemia, and presence of congenital prolongation of the QT interval.
- **Adverse Reactions:** The common adverse reactions ($\geq 2\%$ for NUPLAZID and greater than placebo) were peripheral edema (7% vs 2%), nausea (7% vs 4%), confusional state (6% vs 3%), hallucination (5% vs 3%), constipation (4% vs 3%), and gait disturbance (2% vs <1%).
- **Drug Interactions:**
 - Coadministration with strong CYP3A4 inhibitors (e.g., ketoconazole) increases NUPLAZID exposure. Reduce NUPLAZID dose to 10 mg taken orally as one tablet once daily.
 - Coadministration with strong or moderate CYP3A4 inducers reduces NUPLAZID exposure. Avoid concomitant use of strong or moderate CYP3A4 inducers with NUPLAZID.

See additional Important Safety Information on the previous page. Please read the accompanying full [Prescribing Information](#), including **Boxed WARNING**, also available at [NUPLAZIDhcp.com](https://www.nuplazidhcp.com).

References: 1. Acadia Pharmaceuticals Inc. NUPLAZID® [package insert]. San Diego, CA; 2020. 2. Acadia Pharmaceuticals Inc. NUPLAZID Advisory Committee Briefing Document. San Diego, CA: Sponsor Background Information for a Meeting of the Psychopharmacologic Drugs Advisory Committee; March 29, 2016. <https://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/PsychopharmacologicDrugsAdvisoryCommittee/UCM492453.pdf>. Accessed April 16, 2021.



©2021 Acadia Pharmaceuticals Inc. Acadia and NUPLAZID are registered trademarks of Acadia Pharmaceuticals Inc. All rights reserved. NU-1960-v2 04/21.

ONCE-DAILY
NUPLAZID[®]
(pimavanserin) 34mg capsules